Nanotechnology Now - Press Release: OctoPlus' Annual General Meeting of Shareholders will be held on 20 May in Leiden

Home > Press > OctoPlus' Annual General Meeting of Shareholders will be held on 20 May in Leiden

Abstract:
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO) announces that its Annual General Meeting of Shareholders will be held at the Company's headquarters in Leiden on 20 May 2011 at 2 PM CET. The agenda and other information regarding the AGM are available in the Investor Relations section on the Company's website, www.octoplus.nl.

OctoPlus' Annual General Meeting of Shareholders will be held on 20 May in Leiden

Leiden, the Netherlands | Posted on April 8th, 2011

The Annual Report is also available on the Company's website. Hard copies of the report can be requested by sending an e-mail to Investor Relations at

For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, or send an e-mail to Investor Relations at

####

About OctoPlus N.V.
OctoPlus is a specialty pharmaceutical company committed to the creation of improved pharmaceutical products that are based on OctoPlus’ proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The clinically most advanced product incorporating our technology is Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and has recently completed Phase IIb clinical studies with superior clinical data versus current treatment.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus’ current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words “expect”, “anticipate”, “predict”, “estimate”, “project”, “plan”, “may”, “should”, “would”, “will”, “intend”, “believe” and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

For more information, please click here

Contacts:
OctoPlus N.V.
Zernikedreef 12
2333 CL Leiden
The Netherlands
Phone: +31 (0)71 524 40 44
Fax: +31 (0)71 524 40 43

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: